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The effect of human MutY homolog (hMYH) on the activation 
of checkpoint proteins in response to hydroxyurea (HU) and 
ultraviolet (UV) treatment was investigated in hMYH-disrupted 
HEK293 cells. hMYH-disrupted cells decreased the phosphor-
ylation of Chk1 upon HU or UV treatment and increased the 
phosphorylation of Cdk2 and the amount of Cdc25A, but not 
Cdc25C. In siMYH-transfected cells, the increased rate of 
phosphorylated Chk1 upon HU or UV treatment was lower 
than that in siGFP-transfected cells, meaning that hMYH was 
involved in the activation mechanism of Chk1 upon DNA 
damage. The phosphorylation of ataxia telangiectasia and Rad3- 
related protein (ATR) upon HU or UV treatment was decreased 
in hMYH-disrupted HEK293 and HaCaT cells. Co-immunopre-
cipitation experiments showed that hMYH was immunopre-
cipitated by anti-ATR. These results suggest that hMYH may in-
teract with ATR and function as a mediator of Chk1 phosphor-
ylation in response to DNA damage. [BMB reports 2011; 44(5): 
352-357]
INTRODUCTION
Oxidatively damaged DNA lesions are mainly repaired by 
base excision repair (BER), which is tightly coupled with cell 
cycle regulation and DNA damage checkpoints (1). Human 
MutY homolog (hMYH) is a representative BER DNA glyco-
sylase that removes adenine or 2-hydroxyadenine mismatched 
with guanine or 7,8-dihydroxy-8-oxoguanine (8-oxoG), and 
their removal prevents G:C to T:A transversion (2). Together 
with human 8-oxoG glycosylase (hOGG1) (3) and human 
MutT homolog (hMTH1) (4), hMYH protects cells from the 
mutagenic effects of 8-oxoG. 
    Deficiencies in mouse MYH and OGG1 result in increased 
tumor predisposition, predominantly lung and ovarian tumors 
and lymphomas (5). The MYH-null mouse generates more 
spontaneous tumors, especially oxidative stress-induced in-
testinal tumors compared to wild type (6). Therefore, MYH was 
suggested to suppress spontaneous tumorigenesis in mammals. 
Further, deficiencies in mouse MYH and OGG1 have been 
shown to increase the sensitivity of cells in G2/M phase to oxi-
dants, accompanied by increased centrosome amplification 
and formation of multiple nuclei (7). hMYH was suggested to 
play multiple roles in normal cell cycle progression and cell 
division under oxidative stress and to act as an adaptor mole-
cule that recruits checkpoint proteins to DNA lesions (8). 
However, the effect of hMYH on the activation of checkpoint 
proteins upon DNA damage has not been fully investigated.
    In this study, we determined for the first time the association 
of hMYH with phosphorylation of checkpoint kinase 1 (Chk1) 
and ataxia telangiectasia and Rad3-related protein (ATR) in re-
sponse to DNA damage in hMYH-disrupted HEK293 and 
HaCaT cells. 
RESULTS
Knock-down of hMYH by siRNA 
To investigate the effects of hMYH on DNA damage-induced 
cell cycle regulation, small interfering RNA (siRNA) was em-
ployed in order to deplete endogenous cellular hMYH. Two 
siRNAs (siMYH782 and siMYH1392) corresponding to nucleo-
tides 782-806 and 1392-1416 of hMYH, respectively, were de-
signed and transfected into HEK293 cells. Western blot analy-
sis showed that after 24 h incubation, approximately 90 and 
84% of hMYH were disrupted by siMYH782 and siMYH1392 
transfection, respectively (Fig. 1). Maximal disruption of hMYH 
was obtained after 36 and/or 48 h of transfection (Supple-
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Fig. 1. Knock-down of hMYH using siRNA. HEK293 cells trans-
fected with 500 pmol of siRNAs (siGFP, siMYH782, and siMYH 
1392) were incubated for 24 h. Endogenous hMYH proteins pre-
sented in siRNA-transfected cells were determined by Western 
blot analysis.
Fig. 2. Knock-down of hMYH reduces phosphorylation 
of Chk1 upon HU or UV treatment. (A) HEK293 cells 
were transfected with 500 pmol of siGFP or siMYH 
782. After 36 h incubation, the cells were treated 
with 20 mM HU or 100 J/m2 UV light for 1 h. Total 
proteins were extracted and analyzed by Western blot 
analysis. (B-D) The contents of phospho-Chk1, phos-
pho-Chk2, and Cdc25A obtained from three independent
experiments of (A) were quantified and are repre-
sented as bar diagrams. The value of phospho-Chk1, 
phopho-Chk2, and Cdc25A obtained from siGFP-trans-
fected and HU-treated cells was estimated as 100. 
(E-H) HEK293 cells were transfected with 500 pmol of 
siGFP or siMYH782. After 36 h incubation, the cells 
were treated with 20 mM HU (E, F) or 100 J/m2 UV 
light (G, H) for the indicated times. Total proteins 
were extracted from cells, and phospho-Chk1 and 
Chk1 were analyzed by Western blot analysis.
mentary data 1). Transfection of siMYH782 followed by 36 h 
incubation was selected for use in subsequent experiments in 
order to maximize the disruption of endogenous hMYH.
Depletion of endogenous hMYH reduces phosphorylation of 
Chk1 upon HU or UV treatment 
The effect of hMYH on the phosphorylation of Chk1 and Chk2 
in response to HU or UV treatment was investigated in siGFP 
or siMYH-transfected HEK293 cells. After 36 h siRNA trans-
fection, cells were treated with 20 mM HU or 100 J/m2 UV, 
followed by incubation for 1 h. HU and UV treatment induced 
phosphorylation of Chk1 and Chk2 in siRNA-transfected cells 
(Fig. 2A, lanes 3-6). The phosphorylation of Chk1 by HU and 
UV treatment was decreased by 33.1 and 72.6%, respectively, 
in 87-94% hMYH-disrupted cells (lanes 4 and 6), compared to 
siGFP-transfected cells (lanes 3 and 5). Meanwhile, HU and 
UV treatment increased Chk2 phosphorylation by 20.1 and 
27.6%, respectively (Fig. 2A and C). The total amount of 
Cdc25A in hMYH-disrupted and HU or UV-treated cells was 
increased by 73.5 or 84.5%, respectively (Fig. 2A and D). 
    To further determine the effect of hMYH on the phosphor-
ylation of Chk1, siRNA-transfected cells were treated with HU 
or UV, incubated for 15, 30, 60, 120, 240, or 360 min, and 
analyzed by Western blot analysis (Fig. 2E-H and Supplemen-
tary data 2). Chk1 phosphorylation in siGFP-transfected cells 
was rapidly increased, reaching a maximum 60 min after HU 
or UV treatment and then gradually decreasing thereafter. 
Chk1 phosphorylation in siMYH-transfected cells was also 
maximal at 60 min. However, the increase in phosphorylated 
Chk1 upon HU or UV treatment was slower than that in 
siGFP-transfected cells. Sixty minutes after HU or UV treat-
ment, siMYH-mediated knock-down of endogenous hMYH re-
sulted in 33 or 58% reduction of Chk1 phosphorylation, 
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Fig. 3. Knock-down of hMYH decreases phosphorylation of 
ATR upon HU or UV treatment. (A) Endogenous ATR 
from UV-treated (100 J/m2, 1 h) or non-treated HEK293 
cells was immunoprecipitated with goat IgG or anti-ATR. The
presence of ATR or phospho-ATR in immunoprecipates 
was analyzed by Western blot analysis. (B) Input samples 
used in (A) experiment were determined by Western blot 
analysis. (C) HEK293 cells were transfected with siGFP or 
siMYH782. After 36 h incubation, the cells were treated 
with 20 mM HU or 100 J/m2 UV for 1 h. After immuno-
precipitation of endogenous ATR using anti-ATR, the con-
tents of phospho-ATR and ATR in immunoprecipates were 
analyzed by Western blot analysis. (D) Input samples used 
in (C) experiment were determined by Western blot 
analysis. IP and IB represent immunoprecipitation and im-
munoblotting, respectively.
respectively. Taken together, these results show that hMYH is 
involved in the activation of Chk1 upon DNA damage. 
Depletion of endogenous hMYH reduces the 
phosphorylation of ATR upon HU or UV treatment
To determine the phosphorylation of ATR upon DNA damage, 
cell lysates were prepared from UV-treated cells and im-
munoprecipitated with goat IgG or anti-ATR. The presence of 
phospho-ATR in the immunoprecipitates was determined by 
Western blot analysis. Phospho-ATR was only detected in the 
immunoprecipitate of UV-treated cell lysates using anti-ATR 
(Fig. 3A lane 4). To determine the effect of hMYH on the phos-
phorylation of ATR upon DNA damage, siRNA-transfected 
cells were treated with 20 mM HU or 100 J/m2 UV, followed 
by incubation for 1 h. Cell lysates pre-cleared with protein 
A/G-Sepharose beads were immunoprecipitated with anti-ATR, 
and the presence of ATR and phospho-ATR in the immunopre-
cipitates was determined by Western blot analysis (Fig. 3C). 
Immunoprecipitated ATR was constant regardless of siGFP or 
siMYH transfection and HU or UV treatment. Phospho-ATR 
was detected in HU and UV-treated immunoprecipitate (lanes 
3-6). Phospho-ATR was decreased by 48 and 32% in im-
munoprecipitates of siMYH-transfected cells treated with HU 
and UV, respectively (lanes 4 and 6). The contents of phos-
pho-Chk1, Chk1, hMYH, and ATR in cell lysates were also de-
termined by Western blot analysis (Fig. 3D). 
    To further determine the effect of hMYH on the phosphor-
ylation of ATR, siRNA-transfected HaCaT cells were treated 
with HU or UV, after which the phosphorylation of ATR was 
determined by Western blot analysis (Fig. 4A and B). Endogenous 
hMYH levels in siMYH-transfected cells were decreased by 
about 62%. The phosphorylation of Chk1 by HU and UV treat-
ment was decreased by 64 and 55% in siMYH-transfected cells, 
respectively, compared to siGFP-transfected cells. HU or UV- 
induced phosphorylation of ATR was also determined in hMYH- 
disrupted HaCaT cells. HU or UV treatment induced the phos-
phorylation of ATR, which was dramatically diminished in 
hMYH-disrupted HaCaT cells. Taken together, these results in-
dicate that the disruption of hMYH reduces activation of ATR upon 
HU or UV treatment, thereby reducing the activation of Chk1. 
Endogenous hMYH is co-immunoprecipitated with ATR
The interaction between endogenous hMYH and ATR was de-
termined by co-immunoprecipitation using anti-ATR or an-
ti-hMYH. Western blot analysis showed that hMYH was pres-
ent in the immunoprecipitate of anti-ATR (Fig. 4C lane 2). ATR 
was also co-immunoprecipitated with anti-hMYH (lane 3). 
hMYH and ATR were not detected in the immunoprecipitate 
of goat IgG, which used as a negative control. The presence of 
ATR and hMYH in input cell lysates were determined by 
Western blot analysis (Fig. 4D). This result indicates that 
hMYH may interact with ATR. 
DISCUSSION
Genotoxic stress activates checkpoint signaling pathways that 
block cell cycle progression, trigger apoptosis, and regulate 
DNA repair. Replication stress or other types of DNA damage 
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Fig. 4. hMYH disruption decreases phosphorylation of ATR in HU 
or UV-treated HaCaT cells. (A, B) HaCaT cells were transfected with
500 pmol of siGFP or siMYH782. After 36 h incubation, the cells 
were treated with 20 mM HU (A) or 100 J/m2 UV (B) for 1 h, re-
spectively. Total proteins were extracted and analyzed by Western 
blot analysis. (C, D) HaCaT cell lysates were immunoprecipitated 
with goat IgG, anti-ATR, or anti-hMYH. The presence of ATR or 
hMYH in immunoprecipitates was determined by Western blot 
analysis (C). Endogenous ATR and hMYH levels in cell lysates 
used in (C) experiment were determined by Western blot analysis 
(D).
during S phase promotes the phosphorylation and activation of 
Chk1 through ATR (9). Activated Chk1 plays a critical role in 
the cellular checkpoint response by stabilizing stalled repli-
cation forks, blocking the firing of late origins of replication 
forks, and arresting cells in S or G2/M phase. In this work, the 
phosphorylation of Chk1 in response to HU and UV treatment 
was decreased in hMYH-disrupted cells. Activation of Chk1 
upon DNA damage is induced through the phosphorylation of 
Ser317 and Ser345 by ATR (9). The phosphorylation of Ser317 
was also decreased in hMYH-disrupted cells, similar to Ser345 
(data not shown). Otherwise, HU or UV-induced phosphor-
ylation of Chk2 was slightly increased in hMYH-disrupted 
cells. The inhibition of ATR-Chk1 signaling is known to ele-
vate Chk2 phosphorylation (10). Therefore, this seems to be 
the result of interference in ATR/Chk1 signaling upon hMYH 
depletion. A major target of Chk1 at cell cycle checkpoints is 
Cdc25 phsophatase, which dephosphorylates and activates cy-
clin-dependent kinases (Cdks), thereby promoting cell pro-
gression (11). Regulation of Cdc25 by activated Chk1 even-
tually inhibits Cdks, thereby delaying or arresting the cell cycle 
at specific stages (12). Vertebrates contain three phosphatases, 
Cdc25A, B, and C, all of which can remove the phosphate 
groups from phosphotyrosine and phosphothreonine residues 
for activation of their Cdk substrates (13). Cdc25A plays a 
more general role, being involved in both early (G1/S) and late 
(G2/M) cell-cycle transitions, whereas Cdc25B and Cdc25C 
only regulate the G2/M transition. Cdc25A is also tightly regu-
lated at the protein level, being periodically synthesized and 
degraded via ubiquitin-mediated proteolysis induced by Chk1 
phosphorylation (14). Here, Cdc25A in hMYH-disrupted, HU 
and UV-treated cells was increased, whereas Cdc25C did not 
show any change regardless of HU or UV treatment and hMYH 
disruption (data not shown). These results suggest that hMYH 
may be involved in early (G1/S) and late (G2/M) cell-cycle 
transitions. Endogenous hMYH is known to be increased 3- to 
4-fold during the cell cycle, reaching maximum levels during S 
phase and remaining throughout mitosis (15). In our prelimi-
nary experiment, endogenous hMYH in HEK293 cells was in-
creased during early and/or late G1/S phase and decreased in 
G2/M phase, although a basal level of hMYH was maintained 
during G2/M phase (Supplementary data 3B and D). The knock- 
down of endogenous hMYH by siMYH in asynchronied, early 
G1/S, late G1/S, and G2/M phase cells resulted in 26.7, 22.2, 
46.5, and 65.7% reduction of Chk1 phosphorylation, respec-
tively (Supplementary data 3B and C). Although the highest re-
duction was observed in G2/M phase of hMYH-disrupted cells, 
activation of Chk1 by HU was maximal in late G1/S phase 
cells. Although further study is necessary to evaluate the rule 
of hMYH in cell cycle regulation and Chk1 activation by DNA 
damage, these results suggest that hMYH is mainly involved in 
Chk1 activation by DNA damage during G1/S phase. The acti-
vation of Chk1 can also be induced during G2/M phase and 
reduced by hMYH disruption. 
    In hMYH-disrupted cells, the increased rate of activated 
Chk1 upon HU and UV treatment was lower than that in 
siGFP-transfected cells (Fig. 2E-H). This means that hMYH is 
involved in the activation mechanism of Chk1 upon DNA 
damage, but not in stability or inactivation. Phospho-ATR 
(Ser428), which can be used to confirm the activation of ATR 
upon DNA damage and growth inhibition (16), was decreased 
in immunoprecipitates of siMYH-transfected cells treated with 
HU and UV irradiation. HU and UV-induced ATR phosphor-
ylation were also dramatically diminished in hMYH-disrupted 
HaCaT cells (Fig. 4A, B). This strongly implies that the dis-
ruption of hMYH reduces ATR activation upon HU or UV 
treatment, thereby reducing the activation of Chk1. 
    The activation and recruitment of ATR to DNA lesions can 
be regulated by replication protein A (RPA), ATR interacting 
protein (ATRIP), topoisomerase binding protein 1 (TopBP1), 
and the Rad9-Rad1-Hus1 (9-1-1) complex (17). However, no 
interactions between hMYH and these proteins were observed, 
except for the RPA and 9-1-1 proteins (data not shown). 
Although a direct interaction between ATR and hMYH was not 
obvious, hMYH was shown to interact with ATR. This suggests 
that hMYH interacting with ATR may be involved in the activa-
tion of ATR. hMYH physically and functionally interacts with 
several proteins for its role in replication and DNA repair, such 
as apurinic/apyrimidinic (AP) endonuclease (APE), RPA, and 
mutY homolog 6 (MSH6) (18,19). During checkpoint signaling 
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in response to DNA methylation in S phase, ATR-ATRIP is 
preferentially recruited to O6-MeG/T mismatches in a MutSα 
(a heterodimer of MSH2 and MSH6)- and hMutLα (a hetero-
dimer of MLH1 and PMS2)-dependent manner. Therefore, 
MMR proteins have been suggested to act as direct sensors of 
methylation damage, helping to recruit ATR-ATRIP to sites of 
cytotoxic O6-meG adducts for the initiation of ATR checkpoint 
signaling (20). In addition, MYH was shown to interact with 
the cell cycle checkpoint Rad9-Rad1-Hus1 (9-1-1) complex in 
Schizosaccharomyces pombe, Xenopus, and human (8, 21 and 
22). Human Rad9, Rad1, Hus1, and Rad17 serve as DNA dam-
age sensors by forming DNA damage-responsive complexes 
that clamp around the damaged DNA and transduce damage 
signals to downstream effectors (23), thereby facilitating the ac-
tivation of Chk1 and ATR-mediated phosphorylation (24). The 
fact that MYH can interact with the MSH6 and 9-1-1 complex 
suggests that MYH may play a role in the recognition of DNA 
lesions and signal transduction to checkpoint factors. 
    In conclusion, we demonstrated that hMYH is involved in 
the activation mechanism of Chk1 in response to HU or UV 
treatment, but not stability or inactivation of Chk1. Our results 
suggest that hMYH functions as a mediator of Chk1-associated 
cell cycle checkpoint pathways upon DNA damage. 
MATERIALS AND METHODS
Cell culture
Human embryonic kidney HEK293 and human keratinocyte 
HaCaT cells were cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented 
with 10% fetal bovine serum (FBS; Invitrogen) and 1% pen-
icillin-streptomycin solution (Sigma, St. Louis, MO, USA) at 
37oC in a 5% CO2 incubator. 
siRNA construction and transfection into cells
The optimum siRNA sequences for the knock-down of endoge-
nous hMYH were designed and purchased from the StealthTM 
RNAi program of Invitrogen. siRNA corresponding to nucleo-
tides 415-439 of green fluorescence protein (GFP) was used as 
a negative control. The sequences of siRNA constructed for the 
experiments were: siGFP, 5'-GGGCACAAGCUGGAGUACA-
ACUACA-3'; siMYH782, 5'-CAGGAGAUUUCAACCAAGCA-
GCCAU-3'; siMYH1392, 5'-GGAGGAAUUUCACACCGCA-
GCUGUU-3'. Double-stranded siRNA was prepared by an-
nealing with complementary RNA oligonucleotides. Five hun-
dred picomoles of double-stranded siRNA was transfected into 
50-60% confluent HEK293 or HaCaT cells in 6-well plates us-
ing LipofectamineTM 2000 reagent according to the manu-
facturer’s protocol. 
Protein extraction and Western blot analysis
HEK293 or HaCaT cells were harvested, washed with PBS, 
and lysed with lysis buffer [50 mM Tris-HCl (pH 8.0), 100 mM 
NaCl, 5 mM EDTA, 1 mM NaF, 1 mM Na3VO4, 1% Nonidet 
P-40, 10 μg/ml PMSF, protease, and phosphatase inhibitor 
cocktail (Sigma)] for 1 h at 4oC with occasional vortexing. Protein 
extracts were collected after centrifugation at 16,000 × g for 
20 min. Protein concentration was determined using a Bio-Rad 
DC protein assay kit (Bio-Rad, Hercules, CA, USA). Protein extracts 
resolved on 8 or 10% SDS-polyacrylamide gel were transferred 
onto polyvinylidene difluoride (PVDF) membranes (GE Healthcare, 
Princeton, NJ, USA). The membranes were blocked with 5% 
non-fat dried milk in TBS-T (TBS with 0.05% Tween-20) and 
then incubated with antibodies against ATR, Chk1, Chk2, phospho- 
Chk1 (Ser345), phospho-Chk2 (Thr68), Cdc25A, β-actin (all 
from Santa Cruz Biotech. Santa Cruz, CA, USA), phospho-ATR 
(Ser428; Cell Signaling Technology, Beverly, MA, USA), or hMYH 
(Abnova, Taiwan), followed by incubation with horse-radish 
peroxidase (HRP)-conjugated secondary antibodies (Santa Cruz 
Biotech.). Protein bands were detected using ECL Pico Wes-
tern blotting detection reagents (Pierce, Rockford, IL, USA). 
Immunoprecipitation of ATR
HEK293 cell lysates (2 mg proteins) were pre-cleared with 50 
μl of protein A/G-Sepharose beads (Santa Cruz Biotech.) in or-
der to remove non-specific proteins. After 1 h incubation, cell 
lysates were separated from the beads by centrifugation. 
Pre-cleared supernatants were incubated for 3 h with 4 μg of 
goat IgG (Sigma) or anti-ATR, followed by 12 h incubation 
with 50 μl of protein A/G-Sepharose beads, all at 4oC with 
gentle rotation. Protein-bead complexes were precipitated by 
centrifugation at 600 × g for 5 min, washed five times with 
1：1 mixture of lysis buffer and PBS, and mixed with 2× SDS 
polyacrylamide gel loading buffer. After boiling for 5 min, im-
munoprecipitated samples were resolved on SDS-polyacryla-
mide gel and subjected to Western blot analysis.
Co-immunoprecipitation
Pre-cleared HaCaT cell lysates (2 mg poteins) with 30 μl of 
protein G-Sepharose beads were incubated for 3 h with 2 μg 
of goat IgG, anti-ATR, or anti-hMYH, followed by 12 h in-
cubation with 30 μl of protein A/G-Sepharose beads, all at 4oC 
under gentle rotation. Protein-bead complexes were pre-
cipitated by centrifugation at 600 × g for 5 min, washed five 
times with washing buffer (1：1 mixture of lysis buffer and 
PBS), and mixed with 2× SDS polyacrylamide gel loading 
buffer. After boiling for 5 min, immunoprecipitated samples 
were resolved on SDS polyacrylamide gel and subjected to 
Western blot analysis. 
Statistical analysis
Experiments were performed three times, and statistical analy-
sis was conducted using Student’s t-test. Data are expressed as 
means ± SD. 
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